Clearance of Alzheimer's Abeta peptide: the many roads to perdition - PubMed (original) (raw)
Review
. 2004 Sep 2;43(5):605-8.
doi: 10.1016/j.neuron.2004.08.024.
Affiliations
- PMID: 15339642
- DOI: 10.1016/j.neuron.2004.08.024
Free article
Review
Clearance of Alzheimer's Abeta peptide: the many roads to perdition
R E Tanzi et al. Neuron. 2004.
Free article
Abstract
The amyloid hypothesis of Alzheimer's disease (AD) maintains that the accumulation of the amyloid beta protein (Abeta) is a critical event in disease pathogenesis. A great deal of both academic and commercial research has focused on the mechanisms by which Abeta is generated. However, investigations into the mechanisms underlying Abeta clearance have blossomed over the last several years. This minireview will summarize pathways involved in the removal of cerebral Abeta, including enzymatic degradation and receptor-mediated efflux out of the brain.
Similar articles
- Metabolism of amyloid-beta peptide and Alzheimer's disease.
Iwata N, Higuchi M, Saido TC. Iwata N, et al. Pharmacol Ther. 2005 Nov;108(2):129-48. doi: 10.1016/j.pharmthera.2005.03.010. Epub 2005 Aug 19. Pharmacol Ther. 2005. PMID: 16112736 Review. - Transforming growth factor-beta signaling pathway as a therapeutic target in neurodegeneration.
Wyss-Coray T. Wyss-Coray T. J Mol Neurosci. 2004;24(1):149-53. doi: 10.1385/JMN:24:1:149. J Mol Neurosci. 2004. PMID: 15314264 - Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.
Wang YJ, Zhou HD, Zhou XF. Wang YJ, et al. Drug Discov Today. 2006 Oct;11(19-20):931-8. doi: 10.1016/j.drudis.2006.08.004. Epub 2006 Sep 7. Drug Discov Today. 2006. PMID: 16997144 Review. - Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.
Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, Martins RN. Bates KA, et al. Mol Psychiatry. 2009 May;14(5):469-86. doi: 10.1038/mp.2008.96. Epub 2008 Sep 16. Mol Psychiatry. 2009. PMID: 18794889 Review.
Cited by
- Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease.
Lehmann S, Schraen-Maschke S, Buée L, Vidal JS, Delaby C, Hirtz C, Blanc F, Paquet C, Allinquant B, Bombois S, Gabelle A, Hanon O; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Lehmann S, et al. Mol Neurodegener. 2024 Oct 8;19(1):66. doi: 10.1186/s13024-024-00755-3. Mol Neurodegener. 2024. PMID: 39380095 - Dysregulated expression of miR-140 and miR-122 compromised microglial chemotaxis and led to reduced restriction of AD pathology.
Song C, Li S, Mai Y, Li L, Dai G, Zhou Y, Liang X, Zou OM, Wang Y, Zhou L, Liu J, Zou Y. Song C, et al. J Neuroinflammation. 2024 Jul 2;21(1):167. doi: 10.1186/s12974-024-03162-z. J Neuroinflammation. 2024. PMID: 38956605 Free PMC article. - Recent Advances in the Treatment and Management of Alzheimer's Disease: A Precision Medicine Perspective.
Shukla D, Suryavanshi A, Bharti SK, Asati V, Mahapatra DK. Shukla D, et al. Curr Top Med Chem. 2024;24(19):1699-1737. doi: 10.2174/0115680266299847240328045737. Curr Top Med Chem. 2024. PMID: 38566385 Review. - Simian varicella virus infection and reactivation in rhesus macaques trigger cytokine and Aβ40/42 alterations in serum and cerebrospinal fluid.
Niemeyer CS, Traina-Dorge V, Doyle-Meyers L, Das A, Looper J, Mescher T, Feia B, Medina E, Nagel MA, Mahalingam R, Bubak AN. Niemeyer CS, et al. J Neurovirol. 2024 Feb;30(1):86-99. doi: 10.1007/s13365-024-01196-w. Epub 2024 Mar 7. J Neurovirol. 2024. PMID: 38453879 - Network pharmacology‒based analysis of marine cyanobacteria derived bioactive compounds for application to Alzheimer's disease.
Xie R, Chen F, Ma Y, Hu W, Zheng Q, Cao J, Wu Y. Xie R, et al. Front Pharmacol. 2023 Oct 19;14:1249632. doi: 10.3389/fphar.2023.1249632. eCollection 2023. Front Pharmacol. 2023. PMID: 37927608 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical